The role of CXCL1/CXCR2 axis in neurological diseases.


Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 26 12 2022
revised: 26 04 2023
accepted: 09 05 2023
medline: 16 6 2023
pubmed: 30 5 2023
entrez: 29 5 2023
Statut: ppublish

Résumé

The C-X-C chemokine ligand (CXCL) 1 and its receptor C-X-C chemokine receptor (CXCR) 2 are widely expressed in the peripheral nervous systems (PNS) and central nervous systems (CNS) and are involved in the development of inflammation and pain after various nerve injuries. Once a nerve is damaged, it affects not only the neuron itself but also lesions elsewhere in its dominant site. After the CXCL1/CXCR2 axis is activated, multiple downstream pathways can be activated, such as c-Raf/MAPK/AP-1, p-PKC-μ/p-ILK/NLRP3, JAK2/STAT3, TAK1/NF-κB, etc. These pathways in turn mediate cellular motility state or cell migration. CXCR2 is expressed on the surface of neutrophils and monocytes/macrophages. These cells can be recruited to the lesion through the CXCL1/CXCR2 axis to participate in the inflammatory response. The expression of CXCR2 in neurons can activate some pathways in neurons through the CXCL1/CXCR2 axis, thereby causing damage to neurons. CXCR2 is also expressed in astrocytes, and when CXCR2 activated, it increases the number of astrocytes but impairs their function. Since inflammation can occur at almost any site of injury, elucidating the mechanism of CXCL1/CXCR2 axis' influence on inflammation may provide a favorable target for clinical treatment. Therefore, this article reviews the research progress of the CXCL1/CXCR2 axis in neurological diseases, aiming to provide a more meaningful theoretical basis for the treatment of neurological diseases.

Identifiants

pubmed: 37247498
pii: S1567-5769(23)00653-7
doi: 10.1016/j.intimp.2023.110330
pii:
doi:

Substances chimiques

Chemokine CXCL1 0
NF-kappa B 0
Receptors, Interleukin-8B 0
CXCL1 protein, human 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

110330

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Suli Jiang (S)

Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.

Jie Liang (J)

Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.

Wei Li (W)

Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.

Luoyang Wang (L)

Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.

Meiying Song (M)

Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.

Shuo Xu (S)

Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.

Guixian Liu (G)

Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.

Qiaochu Du (Q)

Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.

Dongchang Zhai (D)

Department of Special Medicine, School of Basic Medical College, Qingdao University, Qingdao, Shandong 266071, PR China.

Lei Tang (L)

Department of Special Medicine, School of Basic Medical College, Qingdao University, Qingdao, Shandong 266071, PR China.

Yanyan Yang (Y)

Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.

Li Zhang (L)

Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.

Bei Zhang (B)

Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China. Electronic address: zhangbei124@aliyun.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH